arrow
M

Montserrat Laguno

hospital clinic barcelona-instituto de investigaciones biomedicas august pi i sunyer
H指数:32
被引数:3,814

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Long-acting cabotegravir and rilpivirine in people with HIV receiving chronic anticoagulation: A real-world case series

长效卡博格韦和利匹韦林在慢性抗凝治疗的HIV感染者中的应用:一项真实世界病例系列

2026-09-150
OAAI
Venezuelan migrants living with HIV in Barcelona: Migration patterns and baseline immunovirological characteristics in a retrospective cohort study

在巴塞罗那的 Venezuelans 移民中的 HIV 感染者:回顾性队列研究中的迁移模式及基线免疫病毒学特征

2026-09-130
OAAI
Switching from etravirine to doravirine in people with HIV harbouring NNRTI resistance-associated mutations: the DorSwitch pilot study

替诺福韦酯转换为多替拉韦酯治疗携带NNRTI耐药相关突变的人类免疫缺陷病毒感染者的DorSwitch探索性研究

2026-09-040
PRE
Community-Associated Methicillin-Resistant Staphylococcus aureus Among Gay, Bisexual, and Other Men Who Have Sex with Men Living with HIV Who Engage in Chemsex in Barcelona, Spain: Epidemiological Patterns and Implications for Infection Control

在西班牙巴塞罗那,参与化学性行为的男同性恋、双性恋及与其他男性发生性行为并感染HIV的男性中社区获得性耐甲氧西林金黄色葡萄球菌的流行病学模式及其感染控制意义

2026-08-190
OAAI
Annual vs semi-annual follow-up in low complexity virologically suppressed people with HIV: a randomized interventional trial

低复杂度病毒学抑制HIV感染者年度与半年随访比较:一项随机干预试验

2026-08-190
OAAI
Effectiveness, Sex Differences, and Patient Experience in Real-World Use of Long-Acting Cabotegravir and Rilpivirine: Results from a Prospective Study

长效卡博特韦和 rilpivirine 在真实世界使用中的有效性、性别差异和患者体验:一项前瞻性研究的结果

2026-06-110
OAAI
Incidence, Clinical Features, and Vaccination Coverage of Pneumococcal Disease in People Living with HIV: A Retrospective Cohort Study (2015–2024)

HIV感染者中肺炎链球菌疾病的发病率、临床特征及疫苗接种覆盖率:一项回顾性队列研究(2015–2024)

2025-12-140
OAAI
The Role of Protease Inhibitors in HIV Treatment: Who Still Needs Them in 2025?

蛋白酶抑制剂在HIV治疗中的作用:2025年谁仍然需要它们?

2025-09-150
OAAI
Long-Term Health Outcomes of People with HIV Engaged in Chemsex: A Prospective Cohort Study on Drug Use, Sexual Behaviour, Sexually-Transmitted Infections and Vulnerability

艾滋病感染者参与化学性行为的长期健康结局:一项关于药物使用、性行为、性传播感染和脆弱性的前瞻性队列研究

2025-08-050
OAAI
Effectiveness, safety and discontinuation rates of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in people with HIV using real-world data: a systematic review and meta-analysis
2024-05-175
PRE
Efficacy and safety of raltegravir plus lamivudine maintenance therapy
2023-12-011
PRE
Tolerability of bictegravir/tenofovir alafenamide/emtricitabine versus dolutegravir/lamivudine as maintenance therapy in a real-life setting
2023-10-244
OA
Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate for Nonoccupational HIV-1 Postexposure Prophylaxis: A Prospective Open-Label Trial (DORAVIPEP)
2023-07-190
OAAI
Long-term evolution in liver disease markers and immune and lipid profiles in vertically HIV/HCV-coinfected youths with sustained viral response after direct-acting antivirals therapy
2023-06-011
OAAI
Sex-based epidemiological and immunovirological characteristics of people living with HIV in current follow-up at a tertiary hospital: a comparative retrospective study, Catalonia, Spain, 1982 to 2020
2023-03-090
OAAI
Simplification from tenofovir disoproxil fumarate plus lamivudine or emtricitabine plus ritonavir-boosted protease inhibitor to ritonavir-boosted atazanavir plus lamivudine in virologically suppressed HIV-infected adults with osteopenia: a pilot study
2022-05-050
PRE